This document aims to provide guidance for public health and laboratory experts in identifying human infections with animal influenza viruses as early as possible to provide early warning and inform risk assessments and public health measures.
This ECDC expert opinion confirms earlier assessments by ECDC and national authorities that there is no significant new evidence to support any changes to the approved indications and recommended use of neuraminidase inhibitors (NAIs) in EU/EEA Member States.
This report which is part of the RAGIDA project (Risk Assessment Guidance for Infectious Diseases transmitted on Aircraft) provides viable options for decision-makers when faced with the choice of whether to contact trace air travellers and crew that were potentially exposed to infectious diseases during a flight.
This set of pandemic preparedness indicators is designed to assist Member States with the assessment of their pandemic preparedness in order to identify gaps, prioritise future investment and monitor progress in those areas that, by international consensus, are deemed the most important.
The generic study protocols presented here summarise all relevant methodological issues related to conducting cohort database studies aimed at measuring vaccine effectiveness for seasonal and A(H1N1)v influenza.
This publication presents the core European protocol for a series of proposed influenza vaccine effectiveness studies. The protocol includes a proposed plan for pooled analysis and has recently been adapted to measure vaccine effectiveness for the pandemic vaccine in 2009-10. Together with its twin publication ‘Protocols for cohort database studies to measure influenza vaccine effectiveness in the EU and EEA Member States’, this publication covers all methodological issues in the design and implementation of vaccine effectiveness studies, both for seasonal and the new A(H1N1)v influenza.
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.